| 1 |
Xu X, Xiang Y, Yang Y, Liu K, Cui Z, Tong X, Chen J, Hou F, Luo Z. The application of tumor cell-derived vesicles in oncology therapy. Clin Transl Oncol 2023;25:364-74. [PMID: 36207510 DOI: 10.1007/s12094-022-02966-w] [Reference Citation Analysis]
|
| 2 |
Nie X, Wu Z, Shang J, Zhu L, Liu Y, Qi Y. Curcumol suppresses endothelial-to-mesenchymal transition via inhibiting the AKT/GSK3β signaling pathway and alleviates pulmonary arterial hypertension in rats. Eur J Pharmacol 2023;943:175546. [PMID: 36706802 DOI: 10.1016/j.ejphar.2023.175546] [Reference Citation Analysis]
|
| 3 |
Xu W, Ding J, Li B, Sun T, You X, He Q, Sheng W. Effects of icariin and curcumol on autophagy, ferroptosis, and lipid metabolism based on miR-7/m-TOR/SREBP1 pathway on prostate cancer. Biofactors 2022. [PMID: 36585763 DOI: 10.1002/biof.1927] [Reference Citation Analysis]
|
| 4 |
Ding J, Wen Y, Yuan X, He X. MicroRNA-mediated reprogramming of glucose, fatty acid and amino acid metabolism in cancer. GENOME INSTAB DIS 2022. [DOI: 10.1007/s42764-022-00078-x] [Reference Citation Analysis]
|
| 5 |
Fang Z, Ding Y, Xue Z, Li P, Li J, Li F. Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review. Discov Oncol 2022;13:74. [PMID: 35962862 DOI: 10.1007/s12672-022-00539-5] [Reference Citation Analysis]
|
| 6 |
Sheng W, Ding J, Liu L, Wang N, Lu B, You X, He Q, Zhou Q, Lin H. Curcumol Inhibits the Development of Prostate Cancer by miR-125a/STAT3 Axis. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-16. [DOI: 10.1155/2022/9317402] [Reference Citation Analysis]
|
| 7 |
Wang J, Jin J, Chen T, Zhou Q. Curcumol Synergizes with Cisplatin in Osteosarcoma by Inhibiting M2-like Polarization of Tumor-Associated Macrophages. Molecules 2022;27:4345. [DOI: 10.3390/molecules27144345] [Reference Citation Analysis]
|
| 8 |
Hu S, Ge M, Zhang S, Jiang M, Hu K, Gao L. Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim-Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer. Front Oncol 2022;12:854596. [PMID: 35433443 DOI: 10.3389/fonc.2022.854596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
